Renal Cell Carcinoma

Alkermes' Nemvaleukin Shows Encouraging Anti-Tumor Activity In Pretreated Kidney Cancer

Bristol Myers, Exelixis Tout Additional Opdivo/Cabometyx Combo Data From Kidney Cancer Trial

Aveo Says Tivozanib Patients Up To 5X More Likely To Experience Long-Term PFS Vs. Nexavar In Kidney Cancer

Bristol Myers, Exelixis Tout Additional Opdivo/Cabometyx Combo Data From Kidney Cancer Trial

Aveo Says Tivozanib Patients Up To 5X More Likely To Experience Long-Term PFS Vs. Nexavar In Kidney Cancer

Merck's Keytruda Wins European Approval For Post-Surgery Kidney Cancer

EMA's CHMP Backs Approval For Merck's Keytruda In Adjuvant Setting For Kidney Cancer

Merck's Keytruda Wins European Approval For Post-Surgery Kidney Cancer

EMA's CHMP Backs Approval For Merck's Keytruda In Adjuvant Setting For Kidney Cancer

Bristol Myers Touts 5-Year Kidney Cancer Data For Opdivo-Yervoy Combo Therapy

Exelixis' Cabometyx Combo Trial Shows Benefit In Kidney Cancer Regardless Of Prior Surgery

Renal Cell Carcinoma Recent News

Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer

Merck's Belzutifan Wins FDA Approval As First Drug For Rare VHL Tumors

Aveo Pharma's Stock Trading Higher On Much Awaited FDA Approval For Tivozanib In Relapsed Kidney Cancer

The FDA has finally approved AVEO Pharmaceuticals Inc’s</

Exelixis Up 50% After Meteroric METEOR Results